Fycompa

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
10-05-2023
Produktens egenskaper Produktens egenskaper (SPC)
10-05-2023

Aktiva substanser:

perampanel

Tillgänglig från:

Eisai GmbH

ATC-kod:

N03AX22

INN (International namn):

perampanel

Terapeutisk grupp:

Antiepileptics, , Other antiepileptics

Terapiområde:

Epilepsies, Partial

Terapeutiska indikationer:

Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Produktsammanfattning:

Revision: 32

Bemyndigande status:

Authorised

Tillstånd datum:

2012-07-23

Bipacksedel

                                69
B. PACKAGE LEAFLET
70
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
FYCOMPA 2 MG, 4 MG, 6 MG, 8 MG, 10 MG, AND 12 MG FILM-COATED TABLETS
Perampanel
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Fycompa is and what it is used for
2.
What you need to know before you take Fycompa
3.
How to take Fycompa
4.
Possible side effects
5.
How to store Fycompa
6.
Contents of the pack and other information
1.
WHAT FYCOMPA IS AND WHAT IT IS USED FOR
Fycompa contains a medicine called perampanel. It belongs to a group
of medicines called
anti epileptics. These medicines are used to treat epilepsy - where
someone has repeated fits (seizures).
It has been given to you by your doctor to reduce the number of fits
that you have.
Fycompa is used in association with other antiepileptic drugs to treat
certain forms of epilepsy:
In adults, adolescents (aged 12 years and older), and children (from 4
to 11 years)
-
It is used to treat fits that affect one part of your brain (called a
“partial seizure”).
-
These partial seizures may or may not then be followed by a fit
affecting all of your brain
(called a “secondary generalisation”).
In adults and adolescents (aged 12 years and older), and children
(from 7 to 11 years)
-
It is also used to treat certain fits that affect all of your brain
from the start (called “generalised
seizures”) and cause convulsions or staring spells.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE FYCOMPA
DO NOT TAKE FYCOMPA:
-
If you have ever developed a severe skin rash or skin peeling
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Fycompa 2 mg film-coated tablets
Fycompa 4 mg film-coated tablets
Fycompa 6 mg film-coated tablets
Fycompa 8 mg film-coated tablets
Fycompa 10 mg film-coated tablets
Fycompa 12 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Fycompa 2 mg film-coated tablets
Each film-coated tablet contains 2 mg perampanel.
Excipient with known effect: Each 2 mg tablet contains 78.5 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 4 mg film-coated tablets
Each film-coated tablet contains 4 mg perampanel.
Excipient with known effect: Each 4 mg tablet contains 157.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 6 mg film-coated tablets
Each film-coated tablet contains 6 mg perampanel.
Excipient with known effect: Each 6 mg tablet contains 151.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 8 mg film-coated tablets
Each film-coated tablet contains 8 mg perampanel.
Excipient with known effect: Each 8 mg tablet contains 149.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 10 mg film-coated tablets
Each film-coated tablet contains 10 mg perampanel.
Excipient with known effect: Each 10 mg tablet contains 147.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 12 mg film-coated tablets
Each film-coated tablet contains 12 mg perampanel.
Excipient with known effect: Each 12 mg tablet contains 145.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Fycompa 2 mg film-coated tablets
Orange, round, biconvex tablet, engraved with E275 on one side and
‘2’ on other side
Fycompa 4 mg film-coated tablets
Red, round, biconvex tablet, engraved with E277 on one side and
‘4’ on other side
Fycompa 6 mg film-coated tablets
Pink, round, biconvex tablet, engrav
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 10-05-2023
Produktens egenskaper Produktens egenskaper bulgariska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 13-01-2021
Bipacksedel Bipacksedel spanska 10-05-2023
Produktens egenskaper Produktens egenskaper spanska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 13-01-2021
Bipacksedel Bipacksedel tjeckiska 10-05-2023
Produktens egenskaper Produktens egenskaper tjeckiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 13-01-2021
Bipacksedel Bipacksedel danska 10-05-2023
Produktens egenskaper Produktens egenskaper danska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 13-01-2021
Bipacksedel Bipacksedel tyska 10-05-2023
Produktens egenskaper Produktens egenskaper tyska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 13-01-2021
Bipacksedel Bipacksedel estniska 10-05-2023
Produktens egenskaper Produktens egenskaper estniska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 13-01-2021
Bipacksedel Bipacksedel grekiska 10-05-2023
Produktens egenskaper Produktens egenskaper grekiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 13-01-2021
Bipacksedel Bipacksedel franska 10-05-2023
Produktens egenskaper Produktens egenskaper franska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 13-01-2021
Bipacksedel Bipacksedel italienska 10-05-2023
Produktens egenskaper Produktens egenskaper italienska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 13-01-2021
Bipacksedel Bipacksedel lettiska 10-05-2023
Produktens egenskaper Produktens egenskaper lettiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 13-01-2021
Bipacksedel Bipacksedel litauiska 10-05-2023
Produktens egenskaper Produktens egenskaper litauiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 13-01-2021
Bipacksedel Bipacksedel ungerska 10-05-2023
Produktens egenskaper Produktens egenskaper ungerska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 13-01-2021
Bipacksedel Bipacksedel maltesiska 10-05-2023
Produktens egenskaper Produktens egenskaper maltesiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 13-01-2021
Bipacksedel Bipacksedel nederländska 10-05-2023
Produktens egenskaper Produktens egenskaper nederländska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 13-01-2021
Bipacksedel Bipacksedel polska 10-05-2023
Produktens egenskaper Produktens egenskaper polska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 13-01-2021
Bipacksedel Bipacksedel portugisiska 10-05-2023
Produktens egenskaper Produktens egenskaper portugisiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 13-01-2021
Bipacksedel Bipacksedel rumänska 10-05-2023
Produktens egenskaper Produktens egenskaper rumänska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 13-01-2021
Bipacksedel Bipacksedel slovakiska 10-05-2023
Produktens egenskaper Produktens egenskaper slovakiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 13-01-2021
Bipacksedel Bipacksedel slovenska 10-05-2023
Produktens egenskaper Produktens egenskaper slovenska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 13-01-2021
Bipacksedel Bipacksedel finska 10-05-2023
Produktens egenskaper Produktens egenskaper finska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 13-01-2021
Bipacksedel Bipacksedel svenska 10-05-2023
Produktens egenskaper Produktens egenskaper svenska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 13-01-2021
Bipacksedel Bipacksedel norska 10-05-2023
Produktens egenskaper Produktens egenskaper norska 10-05-2023
Bipacksedel Bipacksedel isländska 10-05-2023
Produktens egenskaper Produktens egenskaper isländska 10-05-2023
Bipacksedel Bipacksedel kroatiska 10-05-2023
Produktens egenskaper Produktens egenskaper kroatiska 10-05-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 13-01-2021

Sök varningar relaterade till denna produkt

Visa dokumenthistorik